Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

01-03-2012 | original paper

Design and Subject Characteristics in the Federally-Funded Citalopram Trial in Children with Pervasive Developmental Disorders

Auteurs: Lawrence Scahill, James T. McCracken, Karen Bearss, Fay Robinson, Eric Hollander, Bryan King, Joel Bregman, Lin Sikich, Kimberly Dukes, Lisa Sullivan, Evdokia Anagnostou, Craig Donnelly, Young-Shin Kim, Louise Ritz, Deborah Hirtz, Ann Wagner

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 3/2012

Abstract

The Studies to Advance Autism Research and Treatment Network conducted a randomized trial with citalopram in children with Pervasive developmental disorders (PDDs). We present the rationale, design and sample characteristics of the citalopram trial. Subjects (128 boys, 21 girls) had a mean age of 9.3 (±3.12) years; 132 (88.6%) were diagnosed with autistic disorder (4.7% with Asperger’s Disorder; 6.7% with PDD-not otherwise specified). Less than half of the subjects were intellectually disabled; 117 (78.5%) were rated Moderate or Marked on the Clinical Global Impression for Severity. Study measures were similar to previous Research Units on Pediatric Psychopharmacology trials. Subjects in this trial were slightly older and more likely to have complaints of repetitive behavior than participants in RUPP trials.

vorige artikel Time Trends in Reported Autism Spectrum Disorders in Israel, 1986–2005

volgende artikel Brief Report: Making Experience Personal: Internal States Language in the Memory Narratives of Children with and Without Asperger’s Disorder

Aman, M. G., McDougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., et al. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavioral problems. Journal of the American Academic Child Adolescent Psychiatry, 49(12), 1143–1154.CrossRef

Arnold, L. E., Vitiello, B., McDougle, C. J., Scahill, L., Shah, B., Gonzalez, N. M., et al. (2003). Parent-defined target symptoms respond to risperidone in RUPP autism study: Customer approach to clinical trials. Journal of the American Academy of Child Psychiatry, 42(12), 1443–1450.CrossRef

American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington: American Psychiatric Association.

Berry, D. A. (2006). Bayesian clinical trials. Nature Reviews Drug Discovery, 5, 27–36.PubMedCrossRef

Brown, E. C., Aman, M. G., & Havercamp, S. M. (2002). Factor analysis and norms for parent ratings on the aberrant behavior checklist-community for young people in special education. Research in Developmental Disabilities, 23, 45–60.PubMedCrossRef

Collins, L. M., Murphy, S. A., & Strecher, V. (2007). The multiphase optimization strategy (MOST) and the sequential multiple assignment randomized trial (SMART): New methods for more potent e-Health interventions. American Journal of Preventive Medicine, 32(5 Suppl), S112–S118.PubMedCrossRef

Correll, C. U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J. M., & Malhotra, A. K. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA, 302(16), 1765–1773.PubMedCrossRef

Developmental Autism Disabilities Monitoring Network Surveillance Principal Investigators. (2007). Prevalence of autism spectrum disorders—autism and developmental disabilities monitoring network, 14 Sites, united states, 2002. Morbidity and Mortality Weekly Report, 56, 12–28.

Dolen, G., & Bear, M. F. (2008). Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. Journal of Physiology, 586(6), 1503–1508.PubMedCrossRef

Fombonne, E. (2005). Epidemiology of autistic disorder and other pervasive developmental disorders. Journal of Clinical Psychiatry, 6, 3–8.

Gadow, K. D., & Sprafkin, J. (2002). Child symptom inventory–4 screening and norms manual. Stony Brook: Checkmate Plus.

Guy, W. (1976). ECDEU assessment manual for psychopharmacology. Washington: DHEW, NIMH.

Jahromi, L. B., Kasari, C. L., McCracken, J. T., LS-, Lee., Aman, M. G., McDougle, C. J., et al. (2008). Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. Journal Autism Develop Disorders, 38(3), 395–404.

King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., et al. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior. Archives of General Psychiatry, 66(6), 583–590.PubMedCrossRef

Kraemer, H. C., Mintz, J., Noda, A., Tinklenberg, J., & Yesavage, J. A. (2006). Caution regarding the use of pilot studies to guide power calculations for study proposals. Archives of General Psychiatry, 63(5), 484–489.PubMedCrossRef

Lecavalier, L. (2006). Behavior and emotional problems in young people with PDD: Relative prevalence, effects of subject characteristics, and empirical classification. Journal Autism Develop Disorders, 36, 1101–1114.CrossRef

Lord, C., Rutter, M., & LeCouteur, A. (1994). Autism diagnostic interview–revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal Autism Develop Disorders, 24, 659–685.CrossRef

Martin, A., Scahill, L., Anderson, G. M., Aman, M., Arnold, L. E., McCracken, J., et al. (2004). Weight and leptin changes among risperidone-treated youths with autism: 6 month prospective data. American Journal of Psychiatry, 161(6), 1125–1127.PubMedCrossRef

McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, R., et al. (2005). Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. American Journal of Psychiatry, 162, 1142–1148.PubMedCrossRef

Molloy, C. A., & Manning-Courtney, P. (2003). Prevalence of chronic gastrointestinal symptoms in children with autism and autistic spectrum disorders. Autism, 7(2), 165–171.PubMedCrossRef

Mullen, E. (1995). The mullen scales of early learning. Circle Pines: American Guidance Service.

Neuropharm SOFIA results. (2009). www.neuropharm.co.uk/media_centre/news_release. accessed March 24, 2011.

Nikolov, R. N., Bearss, K. E., Lettinga, J., Erickson, C., Rodowski, M., Aman, M. G., et al. (2009). Gastrointestinal symptoms in a sample of children with pervasive developmental disorders. Journal Autism Develop Disorders, 39(3), 405–413.CrossRef

Research Units on Pediatric Psychopharmacology Autism Network. (2005). A randomized controlled crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62, 1266–1274.CrossRef

Roid, G. H., & Miller, L. (1997). Leiter international performance scale-revised: Examiner’s manual. In G. H. Roid & L. J. Miller (Eds.), Leiter international performance scale-revised. Wood Dale: Stoelting Co.

Rossignol, D. A. (2009). Novel and emerging treatments for autism spectrum disorders: A systematic review. Annals of Clinical Psychiatry, 21(4), 213–236.PubMed

Sarhangian, R., Bearss, K., Scahill, L. (2009). For research units of pediatric psychopharmacology autism network. Parent-defined target symptoms in the RUPP Methylphenidate Trial. Presented at the Western Regional Medical School Research Conference, January 30, 2009, Carmel, California.

Scahill, L., & Lord, C. (2004). Subject selection and characterization in clinical trial in children with autism. CNS Spectrums, 9(1), 22–32.PubMed

Scahill, L., Riddle, M. A., McSwiggin-Hardin, M., Ort, S. I., King, R. A., Goodman, W. K., et al. (1997). Children’s yale-brown obsessive compulsive scale: Reliability and validity. Journal of the American Academic Child Adolescen Psychiatry, 36(6), 844–852.CrossRef

Scahill, L., McDougle, C. J., Williams, S. K., Dimitropoulos, A., Aman, M. G., McCracken, J., et al. (2006). The Children’s yale-brown obsessive compulsive scale modified for pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 1114–1123.PubMedCrossRef

Scahill, L., Solanto, M., & McGuire, J. (2008). The science and ethics of placebo in pediatric psychopharmacology. Ethics and Behavior, 18, 266–285.CrossRef

Scahill, L., Aman, M. G., McDougle, C. J., Arnold, L. E., McCracken, J. T., Handen, B., et al. (2009). Trial design challenges when combining medication and parent training in children with pervasive developmental disorders. Journal Autism Develop Disorders, 39(5), 720–729.CrossRef

Slosson, R. L. (1983). Slosson intelligence test. East Aurora: Slosson educational publications.

Sparrow, S., Balla, D., & Cicchetti, D. (1984). Vineland adaptive behavior scales. Circle Pines: American Guidance Service.

Sukhodolsky, D. G., Scahill, L., Gadow, K. D., Arnold, L. E., Aman, M. G., McDougle, C. J., et al. (2007). Parent-rated anxiety symptoms in children with pervasive developmental disorders: Frequency and association with core autism symptoms and cognitive functioning. Journal of Abnormal Child Psychology, 36(1), 117–128.PubMedCrossRef

Research Units on Pediatric Psychopharmacology Autism Network. (2002). Risperidone in children with autism for serious behavioral problems. NEJM, 347, 314–321.CrossRef

Valicenti-McDermott, M., McVicar, K., Rapin, I., Wershil, B. K., Cohen, H., & Shinnar, S. (2006). Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease. Journal of Developmental & Behavioral Pediatrics, 27(2 Suppl), S128–S136.CrossRef

Wechsler, D. (1991). Manual for the wechsler intelligence scale for children (3rd ed.). San Antonio: Psychological Corporation.

Wechsler, D. (2002). Manual for the wechsler preschool & primary scale for intelligence children— (3rd ed.). San Antonio: Psychological Corporation.

Titel: Design and Subject Characteristics in the Federally-Funded Citalopram Trial in Children with Pervasive Developmental Disorders
Auteurs: Lawrence Scahill
James T. McCracken
Karen Bearss
Fay Robinson
Eric Hollander
Bryan King
Joel Bregman
Lin Sikich
Kimberly Dukes
Lisa Sullivan
Evdokia Anagnostou
Craig Donnelly
Young-Shin Kim
Louise Ritz
Deborah Hirtz
Ann Wagner
Publicatiedatum: 01-03-2012
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 3/2012
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-011-1251-8

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 3/2012

Brief Report: Life History and Neuropathology of a Gifted Man with Asperger Syndrome

Metabolic Imbalance Associated with Methylation Dysregulation and Oxidative Damage in Children with Autism

A. Feinstein: A History of Autism: Conversations with the Pioneers

Brief Report: Mediation of Treatment Effect in a Communication Intervention for Pre-School Children with Autism

Time Trends in Reported Autism Spectrum Disorders in Israel, 1986–2005

Brief Report: Making Experience Personal: Internal States Language in the Memory Narratives of Children with and Without Asperger’s Disorder